Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis PXN21
- Development stage
- Phase 4
- Lead developer
- ADM Protexin
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus subtilis PXN21 is a specific probiotic bacterial strain being developed by ADM Protexin for the treatment of Parkinson's disease. Originally isolated from the commercial probiotic Bio-Kult, this strain consists of live bacterial spores that have demonstrated the ability to inhibit, delay, and reverse the aggregation of alpha-synuclein, a hallmark protein in Parkinson's pathology. Preclinical studies in Caenorhabditis elegans suggest the mechanism involves the activation of the DAF-16/FOXO protective pathway and alterations in host sphingolipid metabolism, potentially mediated by bacterial metabolites and biofilm formation in the gut. It is currently being evaluated in Phase 2 clinical trials to assess its impact on the gut microbiome and blood biomarkers in Parkinson's patients.
- Brand names
- Bio-Kult
- Other names
- Bacillus subtilis strain PXN21
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on bacillus subtilis PXN21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis PXN21.